Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaoru Tsuchiya

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Quantitative Imaging in Medicine and Surgery|October 23, 2023
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general populationSakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Diagnostics (Basel, Switzerland)|June 26, 2026
Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance ElastographyShohei Kimura, Yutaka Yasui, Nobuharu Tamaki, et al.
Anticancer Research|August 28, 2024
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular CarcinomaNobuharu Tamaki, Nami Mori, Shintaro Takaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|November 21, 2022
Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertensionKoji Yamashita, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 7, 2022
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinomaHironori Ochi, Masayuki Kurosaki, Kouji Joko, et al.
Investigational New Drugs|August 30, 2024
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinomaNami Mori, Nobuharu Tamaki, Shintaro Takaki, et al.
Investigational New Drugs|September 29, 2021
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practiceYuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 27, 2019
Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinibShun Kaneko, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Investigational New Drugs|March 30, 2023
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study GroupShintaro Takaki, Masayuki Kurosaki, Nami Mori, et al.
Journal of Viral Hepatitis|January 17, 2023
Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapyTaisei Keitoku, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Quantitative Imaging in Medicine and Surgery|October 23, 2023
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general populationSakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Diagnostics (Basel, Switzerland)|June 26, 2026
Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance ElastographyShohei Kimura, Yutaka Yasui, Nobuharu Tamaki, et al.
Anticancer Research|August 28, 2024
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular CarcinomaNobuharu Tamaki, Nami Mori, Shintaro Takaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|November 21, 2022
Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertensionKoji Yamashita, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 7, 2022
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinomaHironori Ochi, Masayuki Kurosaki, Kouji Joko, et al.
Investigational New Drugs|August 30, 2024
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinomaNami Mori, Nobuharu Tamaki, Shintaro Takaki, et al.
Investigational New Drugs|September 29, 2021
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practiceYuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 27, 2019
Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinibShun Kaneko, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Investigational New Drugs|March 30, 2023
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study GroupShintaro Takaki, Masayuki Kurosaki, Nami Mori, et al.
Journal of Viral Hepatitis|January 17, 2023
Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapyTaisei Keitoku, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Pageof 15